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Abstract
Pulmonary carcinoid (PC) tumors are rare tumors that account for approximately 1% 
of all lung cancers. The primary treatment option is surgery, while there is no standard 
treatment for metastatic disease. As the number of PCs diagnosed yearly is increasing, 
there is a need to establish novel therapeutic options. This study aimed to investigate 
programmed death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) expression 
in PC tumors since blocking of the PD-1/PD-L1 pathway is a promising therapeutic option 
in various other malignancies. A total of 168 PC patients treated between 1990 and 2013 
were collected from the Finnish biobanks. After re-evaluation of the tumors, 131 (78%) 
were classified as typical carcinoid (TC) and 37 (22%) as atypical carcinoid (AC) tumors. 
Primary tumor samples were immunohistochemically labeled for PD-1, PD-L1 and CD8. 
High PD-1 expression was detected in 16% of the tumors. PD-L1 expression was detected 
in 7% of TC tumors; all AC tumors were PD-L1 negative. PD-L1 expression was associated 
with mediastinal lymph-node metastasis at the time of diagnosis (P = 0.021) as well as 
overall metastatic potential of the tumor (P = 0.010). Neither PD-1 expression, PD-L1 
expression nor CD8+ T cell density was associated with survival. In conclusion, PD-1 and 
PD-L1 were expressed in a small proportion of PC tumors and PD-L1 expression was 
associated with metastatic disease. Targeting of the PD-1/PD-L1 pathway with immune 
checkpoint inhibitors may thus offer a treatment option for a subset of PC patients.
Introduction
Pulmonary carcinoid (PC) tumors are low- and 
intermediate-grade neoplasms that are subdivided into 
typical carcinoid (TC) and atypical carcinoid (AC) based on 
the mitotic count and presence of necrosis (1). PCs belong 
to pulmonary neuroendocrine tumors together with 
high-grade large-cell neuroendocrine carcinoma (LCNEC) 
and small-cell lung cancer (SCLC). However, PCs 
constitute a totally different entity based on a low number 
of genetic mutations, low metastatic potential and a 
generally good prognosis, especially when resected (2, 3, 4). 
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AC tumors tend to have more metastatic potential and 
thus a more aggressive disease course than TC tumors (2).
The main treatment for local PC tumors is resection 
while metastatic diseases are treated with cytotoxic agents, 
radiation therapy and somatostatin analogs, although 
there is no consensus on these treatments (5). From 
an epidemiological point of view, PCs are rare tumors 
accounting for approximately 1% of all lung cancers (6). 
Still, as the number of PC tumors diagnosed yearly is 
increasing, mainly due to the increased use of imaging 
techniques and general awareness of clinicians, there 
might be a need to establish novel therapeutic options for 
these patients (7).
Over recent decades, several studies have shown that 
the immune system plays a critical role in recognizing and 
eliminating malignant cells. In particular, elevated levels 
of cytotoxic CD8+ T cells in the tumor microenvironment 
have been linked to a good prognosis, for example in 
oral squamous cell carcinoma, triple-negative breast 
cancer and non-small-cell lung cancer (NSCLC) (8, 9, 10). 
Among other inflammatory cells, CD8+ T cells express 
membrane receptor programmed death protein 1 (PD-1), 
which interacts with programmed death ligand 1 (PD-L1) 
expressed for example on the surface of various tumor 
cells and antigen-presenting cells (11). This interaction of 
PD-1 and PD-L1 inhibits an antitumor immune response 
in the tumor microenvironment through downregulation 
of T cell cytokine production and proliferation (11, 12). 
Thus, blockading the PD-1/PD-L1 pathway has become 
a promising therapeutic option for several human 
malignancies (13). Monoclonal antibodies targeting PD-1 
or PD-L1, so called checkpoint inhibitors, are widely used 
in clinical practice in treating, for example, patients with 
melanoma or NSCLC (14, 15). In addition, many clinical 
trials on various cancer types are on-going (13).
Several studies have investigated the expression of 
PD-1 and PD-L1 in SCLC but reports on PC tumors are rare 
and have involved only a limited number of patients (16, 
17, 18, 19, 20, 21). In addition, in most studies PCs have 
been merged with high-grade LCNEC and SCLC which 
behave much more aggressively. As proposed in a recent 
paper, PCs should be studied independently of LCNEC and 
SCLC (22). Thus, we collected a large, retrospective, and 
clinically well-characterized series of surgically resected 
PC tumors to investigate the PD-1 and PD-L1 expression 
as well as the number of CD8+ intratumoral T cells and 




A total of 168 patients operated between 1990 and 2013 
were included in the study. Formalin-fixed and paraffin-
embedded (FFPE) primary tumor samples and 14 metastatic 
samples (12 mediastinal lymph-nodes, pleura and tumor 
tissue adjacent to the superior vena cava) together 
with patient data were retrieved from Helsinki Biobank 
(Helsinki, Finland), Auria Biobank (Turku, Finland) and 
Biobank of Eastern Finland (Kuopio, Finland). Survival 
data were obtained from the Finnish Population Register 
Centre and cause of death data from Statistics Finland. 
Each tumor was re-evaluated from diagnostic whole slides 
by an experienced pulmonary pathologist following the 
2015 classification by the World Health Organization 
(WHO) of pulmonary neuroendocrine tumors (1). 
Neuroendocrine differentiation was confirmed by routine 
immunohistochemical labeling for chromogranin A, 
synaptophysin and pan-cytokeratin.
One hundred and thirty-one patients (78%) were 
diagnosed with TC and 37 (22%) with AC tumors. Surgery 
was the first-line treatment for all patients. Mediastinal 
lymph-node dissection was performed in 128 patients 
(76%). Eleven patients (9%) had histologically confirmed 
lymph-node metastasis at the time of diagnosis, and one 
of them also had a metastatic lesion in the liver and bones. 
In addition, 12 patients developed recurrent tumor or 
distant metastasis in the liver, brain, pleura, mediastinal 
lymph-nodes or bones during follow-up. Table  1 shows 
the clinicopathologic features of the patients.
As the Finnish Biobank Act provides a lawful basis for 
research use of patient samples, a project-specific consent 
was not retrieved. However, this study was approved by the 
Scientific and Ethical Committees of all three biobanks.
Next-generation tissue microarray construction
As presented by Zlobec et  al., next-generation tissue 
microarray (ngTMA) construction involves careful 
TMA planning, digital pathology and automated tissue 
microarraying (23). Briefly, fresh hematoxylin and 
eosin-stained slides were prepared from each FFPE tissue 
sample and digitized using a 20× objective. For primary 
tumors, two representative 1 mm cores from the middle 
of the tumor as well as two from the tumor border were 
selected. For metastatic samples, two 1 mm cores were 
marked. The TMAs were constructed using a TMA Grand 
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Master (3DHISTECH, Budapest, Hungary) or Galileo TMA 
CK4500 microarrayer (Isenet, Milan, Italy).
Immunohistochemistry
Fresh 3.5 µm thick TMA sections were cut with a microtome 
onto positively charged slides. Slides were stained for PD-1 
and PD-L1 at the Department of Pathology in the Central 
Finland Central Hospital and for CD8 at the Department 
of Pathology in the Helsinki University Hospital as part 
of a clinical daily routine. After deparaffinization and 
heat-induced antigen retrieval, sections were incubated 
with anti-PD-1 (1:50; clone SP269; Spring Bioscience, 
Pleasanton, CA, USA), anti-PD-L1 (1:100, clone E1L3N, 
#13684; Cell Signaling Technology) or anti-CD8 (1:50, 
clone 4B11, NCL-L-CD8-4B11; Novocastra/Leica 
Biosystems, Nussloch, Germany). Signal visualization 
for PD-1 and PD-L1 was performed with a Bond Polymer 
Refine Detection Kit (Leica Biosystems) and for CD8 
with ultraView Universal DAB Detection Kit (Ventana 
Medical Systems, Tucson, AZ, USA). All sections were 
counterstained with hematoxylin. Fully automated IHC 
stainer BOND-III (Leica Biosystems) was used for PD-1 and 
PD-L1 and BenchMark Ultra (Ventana Medical Systems) 
for CD8. Tonsil served as a positive control for 
all antibodies.
Scoring of the staining results
PD-1- and PD-L1-stained slides were digitized with 
a NanoZoomer-XR scanner (Hamamatsu Photonics, 
Hamamatsu City, Japan) using a 20× objective. By 
utilizing NDP.view2 (Hamamatsu Photonics) software for 
viewing the slides, TK, MA and TV performed PD-1 and 
PD-L1 scoring manually. No image analysis software was 
used. A traditional light microscope was used if a digitized 
image was insufficient. For the assessment of PD-L1, any 
membranous staining in the tumor cells was evaluated 
and the proportion of the tumor cell number with PD-L1 
staining was scored. As previously described, a score of 
<1% was considered PD-L1 negative, while a score ≥1% 
was considered PD-L1 positive (Fig. 1A) (18). The number 
of PD-1-expressing intratumoral lymphocytes per mm2 
was manually calculated including both dim and bright 
expression (Fig.  1C). Expression was categorized into 
low (≤2 lymphocytes) and into high (>2 lymphocytes) 
expression based on the median number of PD-1-positive 
cells (24).
CD8 stained slides were digitized with Pannoramic 
scanner (3DHISTECH) using a 20× objective. The amount 
of intratumoral CD8+ T cells was assessed with QuPath 
software by utilizing simple tissue detection and fast cell 
count functions as previously described by Bankhead et al. 
Table 1 Clinicopathologic features of the patients.
Variable TC AC All
Sex
 Male 44 (34%) 18 (49%) 62 (37%)
 Female 87 (66%) 19 (51%) 106 (63%)
Age
 Mean 53 55 53
 Median 55 57 56
 Range 19–84 23–77 19–84
Tumor size (cm)
 ≤1 34 (26%) 10 (28%) 44 (26%)
 1.1–2.9 75 (58%) 19 (53%) 94 (57%)
 ≥3 21 (16%) 7 (19%) 28 (17%)
 Not available 1 1 2
Hilar/mediastinal (N1/N2) nodal involvement at diagnosis
 Yes 5 (5%) 6 (18%) 11 (9%)
 No 90 (95%) 27 (82%) 117 (91%)
 Not examined 36 4 40
Distant metastasis
 At diagnosis 0 1 (3%) 1 (1%)
 During follow-up 5 (4%) 7 (19%) 12 (7%)
Ki-67 labeling index
 <1% 51 (40%) 9 (24%) 60 (36%)
 1–2% 64 (50%) 20 (54%) 84 (51%)
 >2% 13 (10%) 8 (22%) 21 (13%)
 Not available 3 3
AC, atypical carcinoid tumor; TC, typical carcinoid tumor.
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and Fumet et  al. (Fig.  1D) (25, 26). Cell counts were 
measured in each replicate TMA spot and an average value of 
CD8+ T cells per mm2 was calculated. Low expression of 
CD8 was defined as less or equal than the median value (24).
Statistical analysis
Differences in dichotomous variables between the groups 
were calculated with the Fisher’s exact test, while the 
Kruskal–Wallis and the Mann–Whitney U tests were used 
for continuous variables. The Kaplan–Meier method with 
a log-rank test was used to estimate cumulative survival 
probabilities. Survival was calculated from the date of 
surgery to the last date of follow-up or death. A P value 
<0.05 was considered statistically significant. Two-tailed 
tests were used. Calculations were performed using IBM 
SPSS Statistics for Windows, Version 24.0 (IBM).
Results
PD-1 and PD-L1 expression in PC tumors
PD-1 expression was observed altogether in 68 (40%) 
tumors (median 2, mean 7, range 1–177 cells per mm2). 
Low expression (≤2 PD-1 positive intratumoral 
lymphocytes) of PD-1 was found in 41 (24%) tumors 
and high expression (>2 PD-1 positive intratumoral 
lymphocytes) in 27 (16%) tumors. High PD-1 expression 
was associated with younger age (median 51, mean 51, 
range 20–70  years versus median 60, mean 58, range 
29–82 years, P = 0.024). PD-1 expression was not associated 
with histological subtype, gender, size of tumor or Ki-67 
labeling index (data not shown).
With the 1% cut-off value, nine tumors (5%) were 
considered PD-L1 positive (Table 2). All AC tumors were 
negative. Of ten primary tumor–metastatic sample pairs, 
two primary tumors were positive for PD-L1. Of the 
corresponding metastatic samples, one was interpreted as 
positive and the other as negative (Fig. 1A and B). PD-L1 
expression was not associated with histological subtype, 
gender, age, size of tumor, Ki-67 labeling index or PD-1 
expression (data not shown).
CD8+ T cell density in PC tumors
The median CD8+ T cell density was 45 cells per mm2 
(mean 74, range 2–823) (Fig.  1D). TC tumors showed 
a slightly lower CD8+ T cell density compared with AC 
tumors (median 45, mean 74, range 2–823 vs median 51, 
mean 78, range 2–478). However, this difference was not 
statistically significant (P = 0.940). CD8+ T cell density was 
not associated with gender, age, size of tumor or Ki-67 
labeling index (data not shown).
Association of PD-1 and PD-L1 expression with 
tumor spread
To study the possible relationship between PD-1 
expression and metastatic disease, we performed the 
statistical analysis on all PC patients as well as on TC and 
Figure 1
Immunohistochemical images of programmed 
death ligand 1 (PD-L1), programmed death 
protein 1 (PD-1) and CD8 staining in pulmonary 
carcinoid tumors. Positive membranous staining 
of PD-L1 in a primary typical carcinoid (TC) tumor 
(A) and in corresponding lymph-node metastasis 
(B). Intratumoral lymphocytes expressing PD-1 in 
a TC tumor (C). A TC tumor with an abundant 
number of intratumoral CD8+ T cells (D). Scale bar 
50 µm, original magnification 40×. Images 
obtained from digitized slides with CaseViewer 
software (3D HISTECH, Budapest, Hungary).
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AC patients separately. There was no difference in the 
PD-1 expression in tumors from patients with metastatic 
disease compared to tumors from patients with non-
metastatic disease.
Next, we examined the PD-L1 expression in TC 
patients with histologically confirmed mediastinal lymph-
node metastasis at the time of diagnosis (n = 5). Altogether, 
mediastinal lymph-node dissection was performed in 95 
(73%) TC patients, of which five had a PD-L1 positive 
tumor. We noticed that tumors expressing PD-L1 were 
accompanied by lymph-node involvements more often 
than PD-L1 negative tumors (n = 89) (2/5, 40% vs 3/89, 
3%, P = 0.021) were. To further examine the association 
of PD-L1 expression with tumor spread, we also included 
the TC patients who developed metastatic disease later 
(n = 4). We observed that tumors expressing PD-L1 were 
accompanied by lymph-node involvement or distant 
metastasis more often than PD-L1 negative tumors (3/9, 
33 vs 3/88, 3%, P = 0.010) were. These data suggest that 
PD-L1 expression is associated with metastatic potential 
in TC tumors.
Association of CD8+ T cell density with 
tumor spread
Furthermore, we studied the possible association of CD8+ 
T cell density with metastatic disease. The median CD8+ 
T cell density was higher in tumors that had metastasized 
into mediastinal lymph-nodes at the time of diagnosis 
compared to non-metastatic tumors (65 vs 43, range 
21–227 and 2–823 cells per mm2, respectively). However, 
this difference was not statistically significant (P = 0.162). 
The same was true when including patients, who 
developed distant metastases during the follow-up (n = 8): 
median CD8+ T cell density was 59 for these tumors and 
44 for tumors without metastasis (P = 0.375). We either 
found no difference in CD8+ T cell density between 
metastatic and non-metastatic tumors when evaluating 
TC and AC patients separately.
Association of PD-1, PD-L1 and CD8+ T cell density 
with survival
The median time for patient follow-up was 11.5  years 
(average 12.7  years, range 1.1–28.0  years). During the 
follow-up, 4 TC patients and 5 AC patients died from 
disease, and 23 patients died from unrelated causes. 
None of the patients whose tumor was expressing PD-L1 
died from disease. Neither PD-1 or PD-L1 expression nor 
CD8+ T cell density was associated with disease-specific 
mortality (data not shown).
Discussion
PCs are uncommon neoplasms with a rising incidence and 
prevalence. This rise together with limited therapeutic 
options for metastatic disease has accentuated the need 
for new treatment strategies. In this regard, the immune 
checkpoint-based therapy targeting PD-1 or PD-L1, that 
has shown its efficacy in other malignancies, could 
be a feasible option for the treatment of metastatic or 
inoperable PC tumors. In the present study, involving the 
so far largest PC tumor cohort published, we evaluated 
immunohistochemically the PD-1 and PD-L1 expression 
together with the intratumoral CD8+ T cell density in a set 
of clinically well-characterized, resected PC tumors.
First, we noticed that PCs, especially TCs, can express 
PD-L1. To the best of our knowledge, only four studies on 
PD-L1 expression in PCs have been published earlier (16, 
18, 20, 21). In all studies, PCs were pooled with LCNEC and 
SCLC, and patient numbers were relatively low, ranging 
from 22 to 57. In particular, AC patients were under-
represented (2, 6, 11 and 18 patients). Three studies used 
whole tissue sections for PD-L1 analysis and one utilized 
TMAs. All studies used different primary antibodies (SP142 
(ZSGB-BIO); E1L3N (Cell Signaling); ab205921 (Abcam) 
and 22C3 (Dako)). In contrast to our results, two of the 
studies observed no PD-L1 expression in PCs even if the 
same primary antibody was used as we did (18, 20). In 
line with our results, Wang et al. found PD-L1 expression 
in 9% of the TC tumors, while all AC tumors were PD-L1 
negative (21). Fan et al. did not differentiate between TC 
and AC but reported that 59% of the PCs expressed PD-L1 
(16). However, they also interpreted cytoplasmic staining, 
Table 2 Histological characteristics of typical carcinoid 
tumors with programmed death ligand 1 (PD-L1) expression.
PD-L1 expressiona PD-1 expressionb Ki-67 (%) Tumor size (cm)
95 0 1 1.0
37 0 <1 1.0
14 2 1 0.9
5 0 <1 2.0
4 177 2 3.0
4 3 4 1.3
4 1 2 2.0
2 1 <1 1.5
1 1 9 1.5
a% of tumor cells expressing membranous PD-L1 staining; bnumber of 
intratumoral PD-1 labeled lymphocytes per mm2.
PD-1, programmed death protein 1.
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while we focused on evaluating only membranous 
staining. The PD-1 expression in PC tumors is less studied 
but Fan et al. reported a 59% positivity for PD-1 in their 
PC tumors and an association between PD-1 expression 
and worse prognosis (16). We found PD-1 positivity in 
16% of the tumors with no association to prognosis.
Secondly, we observed that the PD-L1 expression 
in TC tumors was associated with metastatic disease. 
Previous studies on PCs found no association between 
PD-L1 expression and lymph-node involvement or 
distant metastasis (16, 21). However, neither of the studies 
analyzed PCs separately but merged them with LCNEC 
and SCLC.
We found no association between the PD-L1 
expression and survival, probably due to the low number 
of disease-specific deaths. In contrast, Wang et al. reported 
that the expression of PD-L1 in tumor cells showed a 
trend toward poorer overall survival and progression-free 
survival, although statistical significance was not reached 
in their study either (21). Fan et  al. reported PD-L1 
expression in cancer cells to be an independent favorable 
prognostic factor (16).
As discussed, there are controversial reports on the 
PD-1 and PD-L1 expression and their possible relations to 
tumor spread and disease outcome in PC tumors. However, 
studies indicate that there is a subset of patients whose 
tumors express PD-1 or PD-L1 and that the expression 
associates with patient outcome. Unfortunately, due to 
the lack of standardization of the immunohistochemical 
methods especially in PD-L1 analysis, there is a lot of 
variation in the primary antibodies, staining instruments 
and detection protocols as well as scoring criteria applied. 
The variation partly explains discordant results.
Cancer immunotherapy with monoclonal antibodies 
is a promising treatment especially for melanoma, 
NSCLC and Hodgkin’s lymphoma (27, 28, 29). The 
U.S. Food and Drug Administration has approved two 
checkpoint inhibitors targeting PD-1 (pembrolizumab 
and nivolumab) as well as three PD-L1 targeting agents 
(atezolizumab, avelumab and durvalumab) (30). Of 
these, pembrolizumab has also been studied in patients 
with neuroendocrine tumor. The KEYNOTE-028 
study (NCT02054806) enrolled patients with PD-L1 
positive, well- or moderately differentiated pancreatic 
neuroendocrine tumor (n = 16) or carcinoid tumor (n = 25 of 
which nine were PCs) (31). It showed that pembrolizumab 
is generally well tolerated and that 10% of the patients 
had an objective response. The stable disease rate was 
71%. The efficacy and safety of pembrolizumab was 
also studied in the KEYNOTE-158 study (NCT02628067) 
of patients with well- and moderately differentiated 
neuroendocrine tumor of the lung, appendix, small 
intestine, colon, rectum or pancreas (n = 107) (32). In 
this study, pembrolizumab showed antitumor activity 
with an overall response rate of 3.7% (4/107 patients, 
95% confidence interval 1.0–9.3), all responders having 
a PD-L1-negative tumor. Sixty-one (57%) patients showed 
stable disease as the best response. Both studies show that 
anti-PD-1 monotherapy is beneficial for a subset of NET 
patients. However, as only a limited number of patients 
benefited from the treatment, for example combination 
therapies are needed to potentiate the efficacy of immune 
checkpoint inhibitors. At the moment, PD-L1 expression 
is the best known biomarker for selecting the patients for 
anti-PD1/PD-L1 therapy but for NET patients, it does not 
seem to be an optimal one. Thus, also new predictive 
biomarkers are urgently needed.
There are a couple of limitations in our study. Firstly, 
the number of disease-specific deaths is low, despite the 
relatively long follow-up time, resulting in the fact that 
we could not properly estimate the relation between PD-1, 
PD-L1, CD8+ T cell density and survival. Secondly, we 
used TMAs instead of whole sections and might thus have 
missed some PD-1-or PD-L1-positive areas or hot spots for 
CD8+ T cells despite comprehensive ngTMA approach. 
However, recently Elfving et al. showed that the proportion 
of PD-L1 expression is comparable between resection 
specimens and TMA sections (33). They observed that 
9% of the TMA cases showed different PD-L1 status when 
compared to the resection specimen. In our opinion, the 
use of TMA slides does not influence scientific conclusions 
in studies on large patient series like ours. Thirdly, due 
to the retrospective nature of the study dating back to 
the 1990s, lymph-node dissection was not performed in 
all patients and thus we might have misclassified some 
locally advanced diseases. On the other hand, our study 
comprises a large number of clinically well-characterized 
patients. We also appropriately re-evaluated each tumor 
according to the latest WHO classification and utilized 
clinically validated protocols for immunohistochemical 
labeling of PD-1, PD-L1, and CD8.
In conclusion, our study shows that some PCs, 
especially TCs, express PD-L1, which is associated with 
lymph-node involvement at the time of diagnosis as well 
as overall metastatic potential of the tumor. High PD-1 
expression was found in 16% of the tumors. As only a 
minority of the PC tumors expressed PD-L1 and there was 
only a limited number of intratumoral T cells positive for 
PD-1, monotherapy with PD-1/PD-L1 inhibitors might 
benefit a subset of PC patients.
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